Evidence map›Paper›PMID 38139365›Full record

ReviewInternational journal of molecular sciences2023

Insights into the Tumor Microenvironment-Components, Functions and Therapeutics.

Kornélia Baghy, Andrea Ladányi, Andrea Reszegi, Ilona Kovalszky

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Kornélia BaghyDepartment of Pathology and Experimental Cancer Research, Semmelweis University, 1085 Budapest, Hungary.
Andrea LadányiDepartment of Surgical and Molecular Pathology and the National Tumor Biology Laboratory, National Institute of Oncology, 1122 Budapest, Hungary.ORCID 0000-0001-9304-8473
Andrea ReszegiDepartment of Pediatrics, College of Medicine, University of Florida, Gainesville, FL 32610, USA.
Ilona KovalszkyDepartment of Pathology and Experimental Cancer Research, Semmelweis University, 1085 Budapest, Hungary.ORCID 0000-0002-0179-3378

Funding

National Laboratories Excellence program (under the National Tumor Biology Laboratory project NLP-17)National Research, Development and Innovation Office (Hungary) NKFI FK-138593; NKFI K-119283; NKFI ANN-128524
6 · The paper itself

Abstract

Similarly to our healthy organs, the tumor tissue also constitutes an ecosystem. This implies that stromal cells acquire an altered phenotype in tandem with tumor cells, thereby promoting tumor survival. Cancer cells are fueled by abnormal blood vessels, allowing them to develop and proliferate. Tumor-associated fibroblasts adapt their cytokine and chemokine production to the needs of tumor cells and alter the peritumoral stroma by generating more collagen, thereby stiffening the matrix; these processes promote epithelial-mesenchymal transition and tumor cell invasion. Chronic inflammation and the mobilization of pro-tumorigenic inflammatory cells further facilitate tumor expansion. All of these events can impede the effective administration of tumor treatment; so, the successful inhibition of tumorous matrix remodeling could further enhance the success of antitumor therapy. Over the last decade, significant progress has been made with the introduction of novel immunotherapy that targets the inhibitory mechanisms of T cell activation. However, extensive research is also being conducted on the stromal components and other cell types of the tumor microenvironment (TME) that may serve as potential therapeutic targets.

Indexed as

NeoplasmsTumor MicroenvironmentCarcinogenesisEcosystemHumansImmunotherapyangiogenesisextracellular matriximmune checkpoint inhibitorsproteoglycanstumor-associated fibroblaststumor immunitytumor microenvironmenttumor stroma

Identifiers

PMID38139365
PMCPMC10743805

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.